Brian Tambi

Biography

  Brian Tambi has served on the board of directors of INSYS Therapeutics since November 2007. Mr. Tambi also serves as a member of the board of directors of Akorn Pharmaceuticals Inc., a publicly traded pharmaceutical company. Mr. Tambi has more than 30 years of executive management leadership with companies such as IVAX Corporation, Fujisawa Pharmaceutical Company USA, LyphoMed Inc., and Bristol-Myers International Group. He presently serves as the chairman of the board, and as President and CEO of Antrim Pharmaceuticals LLC, a specialized pharmaceutical company involved in the development of generic oral drugs in specific delivery systems. Partnering with William Blair Capital Partners in 1995, Mr. Tambi purchased Morton Grove Pharmaceuticals for $10.5 million where he served as president, CEO and chairman of the board until it was sold in 2001 for $200 million as a leading manufacturer and marketer of oral liquid and topical pharmaceuticals. Prior to Morton Grove Pharmaceuticals, Mr. Tambi was president of Ivax Pharmaceuticals North America, which was subsequently acquired by Teva Pharmaceutical Industries Ltd. He also served as a member of Ivax’s board of directors. In 1985, he joined Lyphomed Inc. in Chicago, IL as General Manager of a new proprietary drug division to develop a portfolio of patented pharmaceuticals. On the sale of Lyphomed to Fujisawa Pharmaceutical in 1991, Mr. Tambi was appointed Chief Operating Officer of Fujisawa USA. Shortly thereafter, Fujisawa Japan appointed Mr. Tambi to chairman, Worldwide Development Group to develop Prograph, the FDA-approved organ transplant anti-rejection drug. In 2005, Fujisawa merged with Yamanouchi Pharmaceuticals to become Astellas Pharma. During his tenure at Bristol-Myers Company, Mr. Tambi was appointed Director of Business Development, Assistant to the President and a member of Bristol's Management Committee. In 1985, Mr. Tambi joined Bristol-Myers International Division as Director, Business Development and Assistant to the President. Mr. Tambi earned his B.S. in Corporate Finance and his MBA in International Finance and Economics at Syracuse University. 

Research Interest

 organ transplant